This Charter is the operating contract between AimwellBio and the Founding 100. Membership grants privileges. Privilege carries authority. Authority requires terms the company can be held to. These are those terms, in writing, binding while the founder operates the company.
Every output the AimwellBio Federated Health Intelligence Network produces — every verdict, every signal, every brief, every confidence score — carries the source chain that produced it. The cohort can audit any output back to its origin.
No exceptions for performance. No black-box mode. No premium tier that hides the math. If a system cannot show its work, it does not enter the network.
Every consensus verdict the network issues (PROCEED, DELAY, or KILL) shows the dissent. The minority view is never erased, summarized away, or hidden behind the majority. The cohort sees the same dissent every adversarial agent sees.
Confidence without dissent is marketing. AimwellBio does not ship marketing as intelligence.
AimwellBio expects to raise pricing as the network scales and the cost of being wrong in biopharma rises. Whatever rate any recurring tier reaches at any point in the company's life, the Founding 100 retain the rate that was in effect on the day they joined the cohort.
Forever. In writing. Enforceable. No reset on acquisition, recapitalization, or product rebrand.
Every product capability, every methodology change, every pricing shift, every change in the network's operating principles — the cohort sees and comments before public release. 90 days minimum, often longer.
The cohort is in the room where it is being built. Not the room where it is announced.
If two-thirds of the active Founding Cohort believes AimwellBio has materially violated this Charter, the cohort can publish that finding. Publicly. With evidence. AimwellBio will not contest the cohort's right to do so.
The Charter is enforceable because the company cannot silence the cohort. Authority without recourse is not authority.
Your Founding Member badge is portable, citation-eligible, and remains yours even if you leave the network. Your published signals, your authored validations, your peer-reviewed contributions — carry your name, not AimwellBio's brand identity.
The cohort builds reputation through the network. The network does not absorb the reputation of its members.
What position will you hold in the validation layer ten years from now if the cohort that defined it is already named?
Not ready for the cohort? Observer is free for credentialed pros →
Plus: founding members are listed on the acknowledgments page of the methodology paper. The list cannot be retroactively edited.
Hand us anything your team is about to use. We return a source-risk review with every citation traced. No sales call. No follow-up sequence. The review itself is the conversation.
The cohort that defines the validation standard will hold a position that cannot be bought later.
Reserve a Founding Seat · $2,500 →Teams searched documents, reviewed guidance updates, followed trial movement, tracked competitors, and built internal briefs by hand. Slow but auditable. Every claim had a paper trail.
Speed. The same brief that took a week now takes minutes. The trade-off: unsupported claims, stale guidance, missing context, and incomplete summaries can now move into serious decisions before anyone challenges them.
AimwellBio is the verification layer that sits between AI-generated intelligence and the decision someone signs their name to. Source-trace, adversarial review, confidence labels, institutional memory.
Seven ways unsupported scientific intelligence can enter regulatory, clinical, board, and investor workflows. Open to credentialed professionals. No sales sequence, no list-trading.